Florence Brunel, PhDSenior Principal Scientist at Novo Nordisk
Florence was born and raised in France. She obtained a MS from the Ecole Nationale Superieure de Chimie De Montpellier, and then moved to the US. She obtained her Ph.D. with Prof. Arno Spatola at the University of Louisville, where her love of and career in peptides started. She then moved to San Diego to pursue her postdoctoral training with Dr. Phil Dawson at Scripps Research where she continued working with peptides while learning new methodologies such as chemical ligation. Florence then took her interest in turning peptides into drugs to the biotech and pharmaceutical industry at companies like Amylin Pharmaceuticals, Pfizer/CovX and Vertex Pharmaceuticals. Florence is now an employee of Novo Nordisk where her role has evolved into a strategy & portfolio position reviewing new technologies, project prioritization and external collaborations to meet Novo Nordisk’s strategy. Florence remains very active in the peptide community as an elected council member for the American Peptide Society, a board member for TIDES and the elected chair of the 2026 Chemistry and Biology of Peptides Gordon Research Conference.
Chairman’s Remarks: Peptides for Cardio-Metabolic Disorders, 8:25amView Session